Back to today’s briefing

Story perspectives

J&J Faces $400M Tariff Costs, Boosts 2025 Sales Forecast

4/15/2025

22 2

Summary

Story summary

Johnson & Johnson expects $400 million in tariff-related costs for 2025 due to U.S.-China trade tensions impacting its medical technology division.
To counter these effects, the company will invest $55 billion in U.S. pharmaceutical production.
Existing contracts restrict J&J's ability to increase prices, complicating cost management.
Despite these challenges, J&J has raised its 2025 sales forecast to $91-$92 billion, fueled by recent acquisitions.

History

Historical Context

The U.S.-China trade tensions echo the 1930s Smoot-Hawley Tariff, which aimed to protect American industries but led to retaliatory tariffs and a global economic downturn. Johnson & Johnson's rising costs reflect similar past struggles of companies navigating protectionist policies, highlighting the cyclical nature of trade conflicts.

1 of 2

Story summary

Johnson & Johnson expects $400 million in tariff-related costs for 2025 due to U.S.-China trade tensions impacting its medical technology division.
To counter these effects, the company will invest $55 billion in U.S. pharmaceutical production.
Existing contracts restrict J&J's ability to increase prices, complicating cost management.
Despite these challenges, J&J has raised its 2025 sales forecast to $91-$92 billion, fueled by recent acquisitions.

1 / 2